Treating and preventing HIV with generic drugs - Barriers in the United States

Erika G. Martin; Bruce R. Schackman

doi:10.1056/NEJMp1710914

Treating and preventing HIV with generic drugs - Barriers in the United States

Erika G. Martin
, Bruce R. Schackman

Public Administration & Policy

University at Albany

Cornell University

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries. In the United States, numerous legal, clinical, and market factors create barriers to the adoption of generics as well as uncertainty about cost savings.

Original language	English
Pages (from-to)	316-319
Number of pages	4
Journal	New England Journal of Medicine
Volume	378
Issue number	4
DOIs	https://doi.org/10.1056/NEJMp1710914
State	Published - Jan 25 2018

Access to Document

10.1056/NEJMp1710914

Cite this

@article{73d2908b97434e18ba4ee4d1ec38eac3,

title = "Treating and preventing HIV with generic drugs - Barriers in the United States",

abstract = "Most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries. In the United States, numerous legal, clinical, and market factors create barriers to the adoption of generics as well as uncertainty about cost savings.",

author = "Martin, \{Erika G.\} and Schackman, \{Bruce R.\}",

year = "2018",

month = jan,

day = "25",

doi = "10.1056/NEJMp1710914",

language = "English",

volume = "378",

pages = "316--319",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "4",

}

TY - JOUR

T1 - Treating and preventing HIV with generic drugs - Barriers in the United States

AU - Martin, Erika G.

AU - Schackman, Bruce R.

PY - 2018/1/25

Y1 - 2018/1/25

N2 - Most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries. In the United States, numerous legal, clinical, and market factors create barriers to the adoption of generics as well as uncertainty about cost savings.

AB - Most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries. In the United States, numerous legal, clinical, and market factors create barriers to the adoption of generics as well as uncertainty about cost savings.

UR - https://www.scopus.com/pages/publications/85041423008

U2 - 10.1056/NEJMp1710914

DO - 10.1056/NEJMp1710914

M3 - Review article

C2 - 29365306

SN - 0028-4793

VL - 378

SP - 316

EP - 319

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 4

ER -

Treating and preventing HIV with generic drugs - Barriers in the United States

Abstract

Access to Document

Other files and links

Fingerprint

Cite this